![](https://www.worldpharmaceuticals.net/wp-content/themes/goodlife-wp-B2B/images/WhitePaper_Default_icon.png)
The pros and cons of post-authorisation studies
By Euromed
Under European guidelines, all pharmaceutical products receiving or maintaining a marketing authorisation must go through a risk management plan that considers the safety and efficacy of the drug after it has been authorised and made commercially available. Pharmathen considers whether these post-authorisation studies are a burden or an opportunity for industry sustainability.
![](https://www.worldpharmaceuticals.net/wp-content/themes/goodlife-wp-B2B/images/WhitePaper_Default_icon.png)